{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:57:44Z","timestamp":1791619064976,"version":"4.3.4"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA253658"],"award-info":[{"award-number":["R01CA253658"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA199081"],"award-info":[{"award-number":["U54CA199081"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA253658"],"award-info":[{"award-number":["R01CA253658"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA199081"],"award-info":[{"award-number":["U54CA199081"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cancer Center Support Grant"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Nanotechnol."],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite the considerable success of clinically approved immune-based therapies for treating advanced melanoma, a significant fraction of patients are not responsive owing to mechanisms engaged by the tumour to evade the immune system. Here we report the surprising finding that a clinically validated and tunable self-therapeutic ultrasmall silica nanoparticle prolongs survival in a highly resistant melanoma model in combination with interleukin-6 and PD-L1 inhibition through activation of the stimulator of interferon genes\/interleukin-6\/PD-L1 axis and reprogramming of the tumour microenvironment towards a pro-inflammatory phenotype. In a murine model, induction of significant cytotoxic and antitumour inflammatory responses leads to differential activation of immune cell populations in a CD8-dependent manner via type I\/II interferon pathways after systemic particle injection. Importantly, these immunostimulatory responses accompany significant reductions in cell populations and receptors driving suppressive activities. Mechanistic insights highlight the potential clinical utility of this platform to maximize antitumour immunity and efficacy by subverting suppressive components in the tumour microenvironment.<\/jats:p>","DOI":"10.1038\/s41565-025-02083-z","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T10:01:49Z","timestamp":1767002509000},"page":"311-322","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["An ultrasmall core\u2013shell silica nanoparticle improves antitumour immunity and survival by remodelling suppressive melanoma microenvironments"],"prefix":"10.1038","volume":"21","author":[{"given":"Gabriel","family":"De Leon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil A.","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Naguib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reethi","family":"Padmanabhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5396-918X","authenticated-orcid":false,"given":"Tuo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Monette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Socciarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5033-4664","authenticated-orcid":false,"given":"Rachel","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles","family":"Pourbaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3007-4986","authenticated-orcid":false,"given":"Michael","family":"Overholtzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha","family":"Merghoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6934-3755","authenticated-orcid":false,"given":"Ulrich","family":"Wiesner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jedd D.","family":"Wolchok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3147-4391","authenticated-orcid":false,"given":"Michelle S.","family":"Bradbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"2083_CR1","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","volume":"398","author":"MS Carlino","year":"2021","unstructured":"Carlino, M. S., Larkin, J. & Long, G. V. Immune checkpoint inhibitors in melanoma. Lancet 398, 1002\u20131014 (2021).","journal-title":"Lancet"},{"key":"2083_CR2","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-022-00854-y","volume":"20","author":"A Naimi","year":"2022","unstructured":"Naimi, A. et al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun. Signal. 20, 44 (2022).","journal-title":"Cell Commun. Signal."},{"key":"2083_CR3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2016.25","volume":"13","author":"DN Khalil","year":"2016","unstructured":"Khalil, D. N., Smith, E. L., Brentjens, R. J. & Wolchok, J. D. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat. Rev. Clin. Oncol. 13, 273\u2013290 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2083_CR4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41571-019-0308-z","volume":"17","author":"JD Martin","year":"2020","unstructured":"Martin, J. D., Cabral, H., Stylianopoulos, T. & Jain, R. K. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges. Nat. Rev. Clin. Oncol. 17, 251\u2013266 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2083_CR5","doi-asserted-by":"crossref","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","volume":"2","author":"A Haslam","year":"2019","unstructured":"Haslam, A. & Prasad, V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw. Open 2, e192535 (2019).","journal-title":"JAMA Netw. Open"},{"key":"2083_CR6","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1126\/science.1232227","volume":"339","author":"LM Coussens","year":"2013","unstructured":"Coussens, L. M., Zitvogel, L. & Palucka, A. K. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 339, 286\u2013291 (2013).","journal-title":"Science"},{"key":"2083_CR7","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.2703","volume":"14","author":"TF Gajewski","year":"2013","unstructured":"Gajewski, T. F., Schreiber, H. & Fu, Y. X. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14, 1014\u20131022 (2013).","journal-title":"Nat. Immunol."},{"key":"2083_CR8","doi-asserted-by":"crossref","first-page":"201026","DOI":"10.1155\/2010\/201026","volume":"2010","author":"MC Schmid","year":"2010","unstructured":"Schmid, M. C. & Varner, J. A. Myeloid cells in the tumor microenvironment: modulation of tumor angiogenesis and tumor inflammation. J. Oncol. 2010, 201026 (2010).","journal-title":"J. Oncol."},{"key":"2083_CR9","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20, 651\u2013668 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"2083_CR10","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1093\/annonc\/mdx179","volume":"28","author":"T Shekarian","year":"2017","unstructured":"Shekarian, T. et al. Pattern recognition receptors: immune targets to enhance cancer immunotherapy. Ann. Oncol. 28, 1756\u20131766 (2017).","journal-title":"Ann. Oncol."},{"key":"2083_CR11","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41568-022-00462-5","volume":"22","author":"SM Man","year":"2022","unstructured":"Man, S. M. & Jenkins, B. J. Context-dependent functions of pattern recognition receptors in cancer. Nat. Rev. Cancer 22, 397\u2013413 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"2083_CR12","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41392-021-00687-0","volume":"6","author":"D Li","year":"2021","unstructured":"Li, D. & Wu, M. Pattern recognition receptors in health and diseases. Signal Transduct. Target. Ther. 6, 291 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2083_CR13","doi-asserted-by":"crossref","first-page":"e20190347","DOI":"10.1084\/jem.20190347","volume":"217","author":"S Kang","year":"2020","unstructured":"Kang, S., Narazaki, M., Metwally, H. & Kishimoto, T. Historical overview of the interleukin-6 family cytokine. J. Exp. Med. 217, e20190347 (2020).","journal-title":"J. Exp. Med."},{"key":"2083_CR14","volume":"4","author":"MA Huseni","year":"2023","unstructured":"Huseni, M. A. et al. CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy. Cell Rep. Med. 4, 100878 (2023).","journal-title":"Cell Rep. Med."},{"key":"2083_CR15","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41392-024-01868-3","volume":"9","author":"M Yi","year":"2024","unstructured":"Yi, M. et al. Targeting cytokine and chemokine signaling pathways for cancer therapy. Signal Transduct. Target. Ther. 9, 176 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2083_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtm.2018.09.002","volume":"12","author":"Y Xiao","year":"2019","unstructured":"Xiao, Y., Shi, K., Qu, Y., Chu, B. & Qian, Z. Engineering nanoparticles for targeted delivery of nucleic acid therapeutics in tumor. Mol. Ther. Methods Clin. Dev. 12, 1\u201318 (2019).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"2083_CR17","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.mattod.2022.11.007","volume":"62","author":"J Seaberg","year":"2023","unstructured":"Seaberg, J., Clegg, J. R., Bhattacharya, R. & Mukherjee, P. Self-therapeutic nanomaterials: applications in biology and medicine. Mater. Today 62, 190\u2013224 (2023).","journal-title":"Mater. Today"},{"key":"2083_CR18","doi-asserted-by":"crossref","first-page":"CT255","DOI":"10.1158\/1538-7445.AM2023-CT255","volume":"83","author":"WW Ma","year":"2023","unstructured":"Ma, W. W. et al. Abstract CT255: ELU-FR\u03b1-1: a study to evaluate ELU001 in patients with solid tumors that overexpress folate receptor alpha (FR\u03b1). Cancer Res. 83, CT255 (2023).","journal-title":"Cancer Res."},{"key":"2083_CR19","doi-asserted-by":"crossref","first-page":"e211936","DOI":"10.1001\/jamanetworkopen.2021.1936","volume":"4","author":"DK Zanoni","year":"2021","unstructured":"Zanoni, D. K. et al. Use of ultrasmall core-shell fluorescent silica nanoparticles for image-guided sentinel lymph node biopsy in head and neck melanoma: a nonrandomized clinical trial. JAMA Netw. Open 4, e211936 (2021).","journal-title":"JAMA Netw. Open"},{"key":"2083_CR20","first-page":"1795","volume":"13","author":"TC Gardinier","year":"2019","unstructured":"Gardinier, T. C. et al. High-performance chromatographic characterization of surface chemical heterogeneities of fluorescent organic\u2013inorganic hybrid core\u2013shell silica nanoparticles. ACS Nano 13, 1795\u20131804 (2019).","journal-title":"ACS Nano"},{"key":"2083_CR21","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1021\/acs.chemmater.5b01222","volume":"27","author":"K Ma","year":"2015","unstructured":"Ma, K. et al. Control of ultrasmall sub-10 nm ligand-functionalized fluorescent core\u2013shell silica nanoparticle growth in water. Chem. Mater. 27, 4119\u20134133 (2015).","journal-title":"Chem. Mater."},{"key":"2083_CR22","doi-asserted-by":"crossref","first-page":"6840","DOI":"10.1021\/acs.chemmater.7b02009","volume":"29","author":"K Ma","year":"2017","unstructured":"Ma, K. & Wiesner, U. Modular and orthogonal post-PEGylation surface modifications by insertion enabling penta-functional ultrasmall organic-silica hybrid nanoparticles. Chem. Mater. 29, 6840\u20136855 (2017).","journal-title":"Chem. Mater."},{"key":"2083_CR23","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1021\/acs.chemmater.6b00030","volume":"28","author":"K Ma","year":"2016","unstructured":"Ma, K., Zhang, D., Cong, Y. & Wiesner, U. Elucidating the mechanism of silica nanoparticle PEGylation processes using fluorescence correlation spectroscopies. Chem. Mater. 28, 1537\u20131545 (2016).","journal-title":"Chem. Mater."},{"key":"2083_CR24","doi-asserted-by":"crossref","first-page":"43879","DOI":"10.1021\/acsami.9b15195","volume":"11","author":"F Chen","year":"2019","unstructured":"Chen, F. et al. Ultrasmall renally clearable silica nanoparticles target prostate cancer. ACS Appl. Mater. Interfaces 11, 43879\u201343887 (2019).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"2083_CR25","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202305937","volume":"36","author":"JA Erstling","year":"2024","unstructured":"Erstling, J. A. et al. Overcoming barriers associated with oral delivery of differently sized fluorescent core-shell silica nanoparticles. Adv. Mater. 36, e2305937 (2024).","journal-title":"Adv. Mater."},{"key":"2083_CR26","volume":"5","author":"F Chen","year":"2019","unstructured":"Chen, F. et al. Molecular phenotyping and image-guided surgical treatment of melanoma using spectrally distinct ultrasmall core-shell silica nanoparticles. Sci. Adv. 5, eaax5208 (2019).","journal-title":"Sci. Adv."},{"key":"2083_CR27","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.1021\/acsami.7b14362","volume":"10","author":"F Chen","year":"2018","unstructured":"Chen, F. et al. Melanocortin-1 receptor-targeting ultrasmall silica nanoparticles for dual-modality human melanoma imaging. ACS Appl. Mater. Interfaces 10, 4379\u20134393 (2018).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"2083_CR28","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1172\/JCI45600","volume":"121","author":"M Benezra","year":"2011","unstructured":"Benezra, M. et al. Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J. Clin. Invest. 121, 2768\u20132780 (2011).","journal-title":"J. Clin. Invest."},{"key":"2083_CR29","doi-asserted-by":"crossref","first-page":"8269","DOI":"10.1021\/acs.chemmater.7b02567","volume":"29","author":"F Chen","year":"2017","unstructured":"Chen, F. et al. Target-or-clear zirconium-89 labeled silica nanoparticles for enhanced cancer-directed uptake in melanoma: a comparison of radiolabeling strategies. Chem. Mater. 29, 8269\u20138281 (2017).","journal-title":"Chem. Mater."},{"key":"2083_CR30","volume":"9","author":"F Chen","year":"2018","unstructured":"Chen, F. et al. Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer. Nat. Commun. 9, 4141 (2018).","journal-title":"Nat. Commun."},{"key":"2083_CR31","doi-asserted-by":"crossref","first-page":"20021","DOI":"10.1021\/acsnano.2c05342","volume":"16","author":"F Wu","year":"2022","unstructured":"Wu, F. et al. Ultrasmall folate receptor alpha targeted enzymatically cleavable silica nanoparticle drug conjugates augment penetration and therapeutic efficacy in models of cancer. ACS Nano 16, 20021\u201320033 (2022).","journal-title":"ACS Nano"},{"key":"2083_CR32","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1158\/1078-0432.CCR-19-1834","volume":"26","author":"R Juthani","year":"2020","unstructured":"Juthani, R. et al. Ultrasmall core-shell silica nanoparticles for precision drug delivery in a high-grade malignant brain tumor model. Clin. Cancer Res. 26, 147\u2013158 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2083_CR33","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.1158\/1078-0432.CCR-20-0851","volume":"26","author":"B Madajewski","year":"2020","unstructured":"Madajewski, B. et al. Molecular engineering of ultrasmall silica nanoparticle-drug conjugates as lung cancer therapeutics. Clin. Cancer Res. 26, 5424\u20135437 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2083_CR34","first-page":"459","volume":"35","author":"AM Urbanska","year":"2020","unstructured":"Urbanska, A. M. et al. A genomic profile of local immunity in the melanoma microenvironment following treatment with \u03b1 particle-emitting ultrasmall silica nanoparticles. Cancer Biother. Radiopharm. 35, 459\u2013473 (2020).","journal-title":"Cancer Biother. Radiopharm."},{"key":"2083_CR35","volume":"241","author":"X Zhang","year":"2020","unstructured":"Zhang, X. et al. Targeted melanoma radiotherapy using ultrasmall 177Lu-labeled \u03b1-melanocyte stimulating hormone-functionalized core-shell silica nanoparticles. Biomaterials 241, 119858 (2020).","journal-title":"Biomaterials"},{"key":"2083_CR36","doi-asserted-by":"crossref","first-page":"2200209","DOI":"10.1002\/adtp.202200209","volume":"6","author":"L Zhang","year":"2023","unstructured":"Zhang, L. et al. Engineered ultrasmall nanoparticle drug-immune conjugates with \u201chit and run\u201d tumor delivery to eradicate gastric cancer. Adv. Ther. 6, 2200209 (2023).","journal-title":"Adv. Ther."},{"key":"2083_CR37","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/nnano.2016.164","volume":"11","author":"SE Kim","year":"2016","unstructured":"Kim, S. E. et al. Ultrasmall nanoparticles induce ferroptosis in nutrient-deprived cancer cells and suppress tumour growth. Nat. Nanotechnol. 11, 977\u2013985 (2016).","journal-title":"Nat. Nanotechnol."},{"key":"2083_CR38","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1200\/JCO.2003.07.005","volume":"21","author":"R Soiffer","year":"2003","unstructured":"Soiffer, R. et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J. Clin. Oncol. 21, 3343\u20133350 (2003).","journal-title":"J. Clin. Oncol."},{"key":"2083_CR39","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ijc.2910610219","volume":"61","author":"I Hara","year":"1995","unstructured":"Hara, I. et al. Rejection of mouse melanoma elicited by local secretion of interleukin-2: implicating macrophages without T cells or natural killer cells in tumor rejection. Int J. Cancer 61, 253\u2013260 (1995).","journal-title":"Int J. Cancer"},{"key":"2083_CR40","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1158\/0008-5472.CAN-11-1792","volume":"72","author":"AM Lesokhin","year":"2012","unstructured":"Lesokhin, A. M. et al. Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res. 72, 876\u2013886 (2012).","journal-title":"Cancer Res."},{"key":"2083_CR41","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/s41401-022-01010-5","volume":"44","author":"J Tong","year":"2023","unstructured":"Tong, J. et al. Ferroptosis inhibitor liproxstatin-1 alleviates metabolic dysfunction-associated fatty liver disease in mice: potential involvement of PANoptosis. Acta Pharmacol. Sin. 44, 1014\u20131028 (2023).","journal-title":"Acta Pharmacol. Sin."},{"key":"2083_CR42","volume":"1","author":"Z Xie","year":"2021","unstructured":"Xie, Z. et al. Gene set knowledge discovery with Enrichr. Curr. Protoc. 1, e90 (2021).","journal-title":"Curr. Protoc."},{"key":"2083_CR43","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41420-022-01212-0","volume":"8","author":"T Ma","year":"2022","unstructured":"Ma, T. et al. GPX4-independent ferroptosis\u2014a new strategy in disease\u2019s therapy. Cell Death Discov. 8, 434 (2022).","journal-title":"Cell Death Discov."},{"key":"2083_CR44","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1007\/s00018-016-2194-1","volume":"73","author":"JY Cao","year":"2016","unstructured":"Cao, J. Y. & Dixon, S. J. Mechanisms of ferroptosis. Cell. Mol. Life Sci. 73, 2195\u20132209 (2016).","journal-title":"Cell. Mol. Life Sci."},{"key":"2083_CR45","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1084\/jem.20180139","volume":"215","author":"T Li","year":"2018","unstructured":"Li, T. & Chen, Z. J. The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer. J. Exp. Med. 215, 1287\u20131299 (2018).","journal-title":"J. Exp. Med."},{"key":"2083_CR46","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s43018-020-0028-4","volume":"1","author":"JA Carozza","year":"2020","unstructured":"Carozza, J. A. et al. Extracellular cGAMP is a cancer-cell-produced immunotransmitter involved in radiation-induced anticancer immunity. Nat. Cancer 1, 184 (2020).","journal-title":"Nat. Cancer"},{"key":"2083_CR47","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1158\/2159-8290.CD-20-0387","volume":"11","author":"J Li","year":"2021","unstructured":"Li, J. et al. Metastasis and immune evasion from extracellular cGAMP hydrolysis. Cancer Discov. 11, 1212\u20131227 (2021).","journal-title":"Cancer Discov."},{"key":"2083_CR48","doi-asserted-by":"crossref","first-page":"e372","DOI":"10.1002\/cpz1.372","volume":"2","author":"JD Bryant","year":"2022","unstructured":"Bryant, J. D., Lei, Y., VanPortfliet, J. J., Winters, A. D. & West, A. P. Assessing mitochondrial DNA release into the cytosol and subsequent activation of innate immune-related pathways in mammalian cells. Curr. Protoc. 2, e372 (2022).","journal-title":"Curr. Protoc."},{"key":"2083_CR49","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41576-019-0151-1","volume":"20","author":"M Motwani","year":"2019","unstructured":"Motwani, M., Pesiridis, S. & Fitzgerald, K. A. DNA sensing by the cGAS-STING pathway in health and disease. Nat. Rev. Genet. 20, 657\u2013674 (2019).","journal-title":"Nat. Rev. Genet."},{"key":"2083_CR50","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/s41392-021-00613-4","volume":"6","author":"R Zhang","year":"2021","unstructured":"Zhang, R., Kang, R. & Tang, D. The STING1 network regulates autophagy and cell death. Signal Transduct. Target. Ther. 6, 208 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2083_CR51","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41580-020-0244-x","volume":"21","author":"KP Hopfner","year":"2020","unstructured":"Hopfner, K. P. & Hornung, V. Molecular mechanisms and cellular functions of cGAS-STING signalling. Nat. Rev. Mol. Cell Biol. 21, 501\u2013521 (2020).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2083_CR52","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cytogfr.2022.09.003","volume":"68","author":"J Liu","year":"2022","unstructured":"Liu, J. et al. The cGAS-STING pathway: post-translational modifications and functional implications in diseases. Cytokine Growth Factor Rev. 68, 69\u201380 (2022).","journal-title":"Cytokine Growth Factor Rev."},{"key":"2083_CR53","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","volume":"76","author":"JH Cha","year":"2019","unstructured":"Cha, J. H., Chan, L. C., Li, C. W., Hsu, J. L. & Hung, M. C. Mechanisms controlling PD-L1 expression in cancer. Mol. Cell 76, 359\u2013370 (2019).","journal-title":"Mol. Cell"},{"key":"2083_CR54","doi-asserted-by":"crossref","first-page":"1230135","DOI":"10.3389\/fimmu.2023.1230135","volume":"14","author":"C Feng","year":"2023","unstructured":"Feng, C., Zhang, L., Chang, X., Qin, D. & Zhang, T. Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy. Front. Immunol. 14, 1230135 (2023).","journal-title":"Front. Immunol."},{"key":"2083_CR55","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117403","volume":"246","author":"C Bailly","year":"2020","unstructured":"Bailly, C. Regulation of PD-L1 expression on cancer cells with ROS-modulating drugs. Life Sci. 246, 117403 (2020).","journal-title":"Life Sci."},{"key":"2083_CR56","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.4049\/jimmunol.1302821","volume":"192","author":"E Sierra-Filardi","year":"2014","unstructured":"Sierra-Filardi, E. et al. CCL2 shapes macrophage polarization by GM-CSF and M-CSF: identification of CCL2\/CCR2-dependent gene expression profile. J. Immunol. 192, 3858\u20133867 (2014).","journal-title":"J. Immunol."},{"key":"2083_CR57","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.cell.2019.05.041","volume":"178","author":"CH Hsu","year":"2019","unstructured":"Hsu, C. H., Altschuler, S. J. & Wu, L. F. Patterns of early p21 dynamics determine proliferation-senescence cell fate after chemotherapy. Cell 178, 361\u2013373 e312 (2019).","journal-title":"Cell"},{"key":"2083_CR58","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1038\/sj.onc.1207405","volume":"23","author":"VO Melnikova","year":"2004","unstructured":"Melnikova, V. O., Bolshakov, S. V., Walker, C. & Ananthaswamy, H. N. Genomic alterations in spontaneous and carcinogen-induced murine melanoma cell lines. Oncogene 23, 2347\u20132356 (2004).","journal-title":"Oncogene"},{"key":"2083_CR59","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s12276-020-0416-y","volume":"52","author":"A Basit","year":"2020","unstructured":"Basit, A. et al. The cGAS\/STING\/TBK1\/IRF3 innate immunity pathway maintains chromosomal stability through regulation of p21 levels. Exp. Mol. Med. 52, 643\u2013657 (2020).","journal-title":"Exp. Mol. Med."},{"key":"2083_CR60","doi-asserted-by":"crossref","first-page":"5692958","DOI":"10.1155\/2019\/5692958","volume":"2019","author":"S Galati","year":"2019","unstructured":"Galati, S., Boni, C., Gerra, M. C., Lazzaretti, M. & Buschini, A. Autophagy: a player in response to oxidative stress and DNA damage. Oxid. Med. Cell Longev. 2019, 5692958 (2019).","journal-title":"Oxid. Med. Cell Longev."},{"key":"2083_CR61","doi-asserted-by":"crossref","first-page":"262-+","DOI":"10.1038\/s41586-019-1006-9","volume":"567","author":"X Gui","year":"2019","unstructured":"Gui, X. et al. Autophagy induction via STING trafficking is a primordial function of the cGAS pathway. Nature 567, 262-+ (2019).","journal-title":"Nature"},{"key":"2083_CR62","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/s41418-018-0251-z","volume":"26","author":"D Liu","year":"2019","unstructured":"Liu, D. et al. STING directly activates autophagy to tune the innate immune response. Cell Death Differ. 26, 1735\u20131749 (2019).","journal-title":"Cell Death Differ."},{"key":"2083_CR63","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nature20554","volume":"539","author":"O De Henau","year":"2016","unstructured":"De Henau, O. et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kgamma in myeloid cells. Nature 539, 443\u2013447 (2016).","journal-title":"Nature"},{"key":"2083_CR64","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1084\/jem.188.2.277","volume":"188","author":"WW Overwijk","year":"1998","unstructured":"Overwijk, W. W. et al. gp100\/pmel 17 is a murine tumor rejection antigen: induction of \u201cself\u201d-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188, 277\u2013286 (1998).","journal-title":"J. Exp. Med."},{"key":"2083_CR65","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1158\/1078-0432.CCR-21-4053","volume":"28","author":"V Aragon-Sanabria","year":"2022","unstructured":"Aragon-Sanabria, V. et al. Ultrasmall nanoparticle delivery of doxorubicin improves therapeutic index for high-grade glioma. Clin. Cancer Res. 28, 2938\u20132952 (2022).","journal-title":"Clin. Cancer Res."},{"key":"2083_CR66","doi-asserted-by":"crossref","first-page":"e000285","DOI":"10.1136\/jitc-2019-000285","volume":"8","author":"W Zhang","year":"2020","unstructured":"Zhang, W. et al. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma. J. Immunother. Cancer 8, e000285 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"2083_CR67","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1038\/s41418-019-0302-0","volume":"26","author":"CX Zhang","year":"2019","unstructured":"Zhang, C. X. et al. STING signaling remodels the tumor microenvironment by antagonizing myeloid-derived suppressor cell expansion. Cell Death Differ. 26, 2314\u20132328 (2019).","journal-title":"Cell Death Differ."},{"key":"2083_CR68","volume":"18","author":"Y Zhu","year":"2019","unstructured":"Zhu, Y. et al. STING: a master regulator in the cancer-immunity cycle. Mol. Cancer 18, 152 (2019).","journal-title":"Mol. Cancer"},{"key":"2083_CR69","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.1039\/C9BM00653B","volume":"7","author":"Y Li","year":"2019","unstructured":"Li, Y. et al. Nanoparticle ferritin-bound erastin and rapamycin: a nanodrug combining autophagy and ferroptosis for anticancer therapy. Biomater. Sci. 7, 3779\u20133787 (2019).","journal-title":"Biomater. Sci."},{"key":"2083_CR70","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.chembiol.2019.01.008","volume":"26","author":"Y Zhang","year":"2019","unstructured":"Zhang, Y. et al. Imidazole ketone erastin induces ferroptosis and slows tumor growth in a mouse lymphoma model. Cell Chem. Biol. 26, 623\u2013633 e629 (2019).","journal-title":"Cell Chem. Biol."},{"key":"2083_CR71","doi-asserted-by":"crossref","first-page":"12380","DOI":"10.1021\/acsnano.8b06399","volume":"12","author":"S Wang","year":"2018","unstructured":"Wang, S. et al. Arginine-rich manganese silicate nanobubbles as a ferroptosis-inducing agent for tumor-targeted theranostics. ACS Nano 12, 12380\u201312392 (2018).","journal-title":"ACS Nano"},{"key":"2083_CR72","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.smim.2017.09.011","volume":"34","author":"Y Liu","year":"2017","unstructured":"Liu, Y., Hardie, J., Zhang, X. & Rotello, V. M. Effects of engineered nanoparticles on the innate immune system. Semin. Immunol. 34, 25\u201332 (2017).","journal-title":"Semin. Immunol."},{"key":"2083_CR73","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1021\/nn5062029","volume":"9","author":"K Shao","year":"2015","unstructured":"Shao, K. et al. Nanoparticle-based immunotherapy for cancer. ACS Nano 9, 16\u201330 (2015).","journal-title":"ACS Nano"},{"key":"2083_CR74","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jconrel.2016.01.020","volume":"240","author":"YN Zhang","year":"2016","unstructured":"Zhang, Y. N., Poon, W., Tavares, A. J., McGilvray, I. D. & Chan, W. C. W. Nanoparticle-liver interactions: cellular uptake and hepatobiliary elimination. J. Control. Release 240, 332\u2013348 (2016).","journal-title":"J. Control. Release"},{"key":"2083_CR75","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.apsb.2022.07.009","volume":"13","author":"R Han","year":"2023","unstructured":"Han, R., Xiao, Y., Bai, Q. & Choi, C. H. J. Self-therapeutic metal-based nanoparticles for treating inflammatory diseases. Acta Pharm. Sin. B 13, 1847\u20131865 (2023).","journal-title":"Acta Pharm. Sin. B"},{"key":"2083_CR76","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3390\/pharmaceutics13060837","volume":"13","author":"O Mijanovic","year":"2021","unstructured":"Mijanovic, O. et al. Cathepsin D\u2014managing the delicate balance. Pharmaceutics 13, 837 (2021).","journal-title":"Pharmaceutics"},{"key":"2083_CR77","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.cell.2012.08.036","volume":"151","author":"X Wang","year":"2012","unstructured":"Wang, X. et al. TPC proteins are phosphoinositide-activated sodium-selective ion channels in endosomes and lysosomes. Cell 151, 372\u2013383 (2012).","journal-title":"Cell"},{"key":"2083_CR78","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.tibs.2018.10.006","volume":"44","author":"P Li","year":"2019","unstructured":"Li, P., Gu, M. & Xu, H. Lysosomal ion channels as decoders of cellular signals. Trends Biochem. Sci. 44, 110\u2013124 (2019).","journal-title":"Trends Biochem. Sci."},{"key":"2083_CR79","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/2211-5463.13385","volume":"12","author":"T Reinheckel","year":"2022","unstructured":"Reinheckel, T. & Tholen, M. Low-level lysosomal membrane permeabilization for limited release and sublethal functions of cathepsin proteases in the cytosol and nucleus. FEBS Open Bio 12, 694\u2013707 (2022).","journal-title":"FEBS Open Bio"},{"key":"2083_CR80","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.immuni.2024.03.002","volume":"57","author":"M Ma","year":"2024","unstructured":"Ma, M., Jiang, W. & Zhou, R. DAMPs and DAMP-sensing receptors in inflammation and diseases. Immunity 57, 752\u2013771 (2024).","journal-title":"Immunity"},{"key":"2083_CR81","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41580-019-0185-4","volume":"21","author":"A Ballabio","year":"2020","unstructured":"Ballabio, A. & Bonifacino, J. S. Lysosomes as dynamic regulators of cell and organismal homeostasis. Nat. Rev. Mol. Cell Biol. 21, 101\u2013118 (2020).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2083_CR82","doi-asserted-by":"crossref","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","volume":"6","author":"T Tanaka","year":"2014","unstructured":"Tanaka, T., Narazaki, M. & Kishimoto, T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb. Perspect. Biol. 6, a016295 (2014).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"2083_CR83","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41392-023-01328-4","volume":"8","author":"H Yan","year":"2023","unstructured":"Yan, H., Lu, W. & Wang, F. The cGAS-STING pathway: a therapeutic target in chromosomally unstable cancers. Signal Transduct. Target. Ther. 8, 45 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2083_CR84","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1158\/0008-5472.CAN-18-0118","volume":"78","author":"H Tsukamoto","year":"2018","unstructured":"Tsukamoto, H. et al. Combined blockade of IL6 and PD-1\/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment. Cancer Res. 78, 5011\u20135022 (2018).","journal-title":"Cancer Res."},{"key":"2083_CR85","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ccell.2022.04.004","volume":"40","author":"Y Hailemichael","year":"2022","unstructured":"Hailemichael, Y. et al. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell 40, 509\u2013523.e506 (2022).","journal-title":"Cancer Cell"},{"key":"2083_CR86","doi-asserted-by":"crossref","first-page":"e007530","DOI":"10.1136\/jitc-2023-007530","volume":"11","author":"MF Soler","year":"2023","unstructured":"Soler, M. F., Abaurrea, A., Azcoaga, P., Araujo, A. M. & Caffarel, M. M. New perspectives in cancer immunotherapy: targeting IL-6 cytokine family. J. Immunother. Cancer 11, e007530 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"2083_CR87","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2022.04.010","volume":"40","author":"J Delyon","year":"2022","unstructured":"Delyon, J. & Lebbe, C. IL-6 blockade in cancer patients treated with immune checkpoint blockade: a win-win strategy. Cancer Cell 40, 450\u2013451 (2022).","journal-title":"Cancer Cell"},{"key":"2083_CR88","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature24050","volume":"550","author":"Z Dou","year":"2017","unstructured":"Dou, Z. et al. Cytoplasmic chromatin triggers inflammation in senescence and cancer. Nature 550, 402\u2013406 (2017).","journal-title":"Nature"},{"key":"2083_CR89","doi-asserted-by":"crossref","first-page":"eabn6612","DOI":"10.1126\/sciimmunol.abn6612","volume":"8","author":"B Jneid","year":"2023","unstructured":"Jneid, B. et al. Selective STING stimulation in dendritic cells primes antitumor T cell responses. Sci. Immunol. 8, eabn6612 (2023).","journal-title":"Sci. Immunol."},{"key":"2083_CR90","doi-asserted-by":"crossref","first-page":"3","DOI":"10.14806\/ej.17.1.200","volume":"17","author":"M Martin","year":"2011","unstructured":"Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet.journal 17, 3 (2011).","journal-title":"EMBnet.journal"},{"key":"2083_CR91","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"2083_CR92","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders, S., Pyl, P. T. & Huber, W. HTSeq\u2014a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166\u2013169 (2015).","journal-title":"Bioinformatics"},{"key":"2083_CR93","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"2083_CR94","doi-asserted-by":"crossref","unstructured":"Blighe, K., Rana, S. & Lewis, M. EnhancedVolcano: publication-ready volcano plots with enhanced colouring and labeling. R package. GitHub https:\/\/github.com\/kevinblighe\/EnhancedVolcano (2023).","DOI":"10.32614\/CRAN.package.ggvolcano"},{"key":"2083_CR95","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics 16, 284\u2013287 (2012).","journal-title":"Omics"},{"key":"2083_CR96","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ymeth.2023.09.004","volume":"219","author":"R Cohen","year":"2023","unstructured":"Cohen, R. et al. Optimising multiplex immunofluorescence staining for characterising the tumour immune micro-environment. Methods 219, 48\u201357 (2023).","journal-title":"Methods"},{"key":"2083_CR97","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/978-1-0716-3163-8_16","volume":"2660","author":"JJ McGue","year":"2023","unstructured":"McGue, J. J., Edwards, J. J., Griffith, B. D. & Frankel, T. L. Multiplex fluorescent immunohistochemistry for preservation of tumor microenvironment architecture and spatial relationship of cells in tumor tissues. Methods Mol. Biol. 2660, 235\u2013246 (2023).","journal-title":"Methods Mol. Biol."}],"container-title":["Nature Nanotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41565-025-02083-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41565-025-02083-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41565-025-02083-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:07:18Z","timestamp":1771477638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41565-025-02083-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":97,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2083"],"URL":"https:\/\/doi.org\/10.1038\/s41565-025-02083-z","relation":{},"ISSN":["1748-3387","1748-3395"],"issn-type":[{"value":"1748-3387","type":"print"},{"value":"1748-3395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"19 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.S.B., M.O. and U.W. are inventors on patent applications related to ferroptosis: Methods of Treatment Using Ultrasmall Nanoparticles to Induce Cell Death of Cancer Cells via Ferroptosis; Methods of Cancer Treatment via Regulated Ferroptosis. M.S.B., U.W., M.O. and G.D.L. are inventors on patent applications related to work on the tumour microenvironment, immunomodulatory nanoparticle conjugates and immunotherapies: Inducing Favorable Effects on Tumor Microenvironment via Administration of Nanoparticle Compositions; Nanoparticle-Mediated Enhancement of Immunotherapy to Promote Ferroptosis-induced Cytotoxicity and Anti-tumor Immune Responses. M.S.B., U.W. and F.C. are listed as inventors on the following patent: Ultrasmall Nanoparticles Labeled with Zirconium-89 and Methods Thereof. J.D.W. is a consultant for Apricity; Ascentage Pharma; AstraZeneca; BeiGene; Bicara Therapeutics; Bristol Myers Squibb; Daiichi Sankyo; Dragonfly; Imvaq; Larkspur; Takeda; Tizona; Trishula Therapeutics; and Immunocore (Data Safety Board). J.D.W. received Grant\/Research Support from Bristol Myers Squibb and Enterome. J.D.W. has Equity in Apricity, Arsenal IO\/CellCarta; Ascentage; Imvaq; Linneaus, Larkspur; Georgiamune; Maverick; Tizona Therapeutics; and Xenimmune. J.D.W. is an inventor on the following patents: Xenogeneic DNA Vaccines; Newcastle Disease Viruses for Cancer Therapy; Myeloid-derived Suppressor Cell (MDSC) Assay; Prediction of Responsiveness to Treatment with Immunomodulatory Therapeutics and Method of Monitoring Abscopal Effects During Such Treatment; anti-PD1 antibody; anti-CTLA4 antibodies; anti-GITR antibodies and methods of use thereof. T.M. is a consultant for Immunos Therapeutics, Daiichi Sankyo Co., TigaTX, Normunity and Pfizer. T.M. is a co-founder of and equity holder in IMVAQ Therapeutics. T.M. receives research grants funding from Bristol Myers Squibb, Surface Oncology, Kyn Therapeutics, Infinity Pharmaceuticals, Peregrine Pharmaceuticals, Adaptive Biotechnologies, Leap Therapeutics and Aprea Therapeutics. T.M. is an inventor on patent applications related to work on oncolytic viral therapy, alpha virus-based vaccine, neoantigen modelling, CD40, GITR, OX40, PD-1 and CTLA-4. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}